Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|November 26, 2006

PET/CT colonography outperforms CT colonography for tumor staging

The assumption that CT colonography is the logical choice for pairing with optical colonoscopy to stage colorectal cancer took a hit at the RSNA meeting today. A prospective study from Europe shows that whole-body FDG-PET/CT is significantly more accurate than CT colonography for staging colorectal tumors.

The assumption that CT colonography is the logical choice for pairing with optical colonoscopy to stage colorectal cancer took a hit at the RSNA meeting today. A prospective study from Europe shows that whole-body FDG-PET/CT is significantly more accurate than CT colonography for staging colorectal tumors.

The study of 52 patients performed by Dr. Peter Veit at the University of Essen in Germany found that whole-body FDG-PET/CT colonography was 74% sensitive for T-staging, compared with a sensitivity rate for CT colonography of 52%. The results were confirmed by histopathology specimens and clinical follow-up 310 days after the initial evaluation. Veit has since joined the nuclear medicine residency program at the University of Zurich in Switzerland.

FDG-PET/CT colonography contributed to alteration of the clinical management of four patients, Veit said. In one instance, PET/CT colonography uncovered a second liver metastasis that was not detected with CT colonography alone. That finding identified the need for a second surgical session to resect the second lesion.

No significant differences in metastasis or lymph node staging were observed.

PET/CT colonography takes about seven minutes longer than the conventional 30-second PET/CT whole-body protocol for colorectal cancer staging, Veit said. Additional time is needed for pharmacological bowel relaxation and rectal water filling.


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.